NewAmsterdam Pharma (NAMS) Retained Earnings (2021 - 2026)

NewAmsterdam Pharma has disclosed Retained Earnings across 6 years of filings, most recently posting -$810.8 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$810.8 million, down 18386.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$810.8 million (down 18386.67% YoY), and the FY2025 annual result was -$762.4 million, down 36.49% from the prior year.
• Retained Earnings came in at -$810.8 million for Q1 2026 at NewAmsterdam Pharma, down from -$762.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $4.8 million in Q4 2022 to a low of -$810.8 million in Q1 2026.
• The 5-year median for Retained Earnings is -$311.2 million (2023), against an average of -$322.4 million.
• Across the five-year window, Retained Earnings jumped 112.06% in 2022 and slumped 18386.67% in 2026, its largest moves.
• NewAmsterdam Pharma's Retained Earnings stood at $4.8 million in 2022, then slipped by 7.61% to $4.4 million in 2023, then sank by 12731.64% to -$558.6 million in 2024, then slumped by 36.49% to -$762.4 million in 2025, then retreated by 6.35% to -$810.8 million in 2026.
• The last three Retained Earnings figures came in at -$810.8 million (Q1 2026), -$762.4 million (Q4 2025), and -$687.5 million (Q3 2025), per Business Quant data.